The BCMA-specific biparatopic nanobody of Ciltacel, in contrast, is expressed as a cell surface receptor on transduced T-cells and is intended for long-term treatment of BCMA-expressing multiple myeloma. Here, CD177 is linked to AL amyloidosis.